Introduction: Gastric cancer is the fifth most common malignancy worldwide and one of the leading causes of cancer-related mortality. This study aimed to evaluate the prognostic impact of the extent of lymphadenectomy in patients undergoing gastrectomy for gastric adenocarcinoma, with emphasis on the correlation between clinical variables and survival. Methods: This was a retrospective, observational study based on the analysis of 200 medical records of patients treated between 2019 and 2024 at a university hospital in the state of Pará, Brazil. Sociodemographic, clinical, histopathological, and surgical data were collected. Statistical analyses included Student's t-test, Mann-Whitney U test, chi-square test, Spearman's correlation, and Kaplan-Meier survival analysis. Results: The mean age of patients was 60.1 years, with 64.5% being male. Most underwent total (50.5%) or subtotal (48%) gastrectomy. According to Lauren’s classification, the intestinal type was the most frequent (52.5%). The mean number of resected lymph nodes was 23.53 (±11.09), with a mean of 5.55 (±8.05) metastatic nodes. Patients with up to two affected lymph nodes had better survival, whereas those with more than 21 positive nodes did not survive beyond two years. The overall five-year survival rate was approximately 50%. A significant correlation was found between the lymph node ratio and mortality (p = 0.041). Neoadjuvant treatment was administered in 56.5% of cases and was associated with lower mortality (p = 0.003), especially among patients with moderate nodal involvement. The platelet-to-lymphocyte ratio (PLR) was also significantly associated with mortality (U = 3887, p = 0.041). A strong correlation was observed between Lauren and WHO classifications (r = 0.90), while clinical variables showed weak associations with the extent of lymphadenectomy. Conclusion: The extent of lymphadenectomy and the number of metastatic lymph nodes are relevant prognostic factors in gastric cancer. Adequate lymph node dissection contributes to more accurate staging and may improve oncological outcomes. Neoadjuvant chemotherapy showed a positive impact on survival in selected subgroups. The inclusion of hematological markers such as PLR may also aid in risk stratification.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
